HK Stock Market Move | INNOCARE(09969) rises by over 11% again, Osimertinib increases significantly with growth in BD income. The company achieves profit for the first time.

INNOCARE (09969) rose by more than 11%, as of the time of publication, it was up by 11.08% to HK$13.15, with a turnover of HK$155 million. On the news front, INNOCARE announced a profit outlook, expecting to achieve revenue of HK$2.37 billion in 2025, representing a year-on-year growth of approximately 134%; it is also expected to turn a profit for the first time in 2025, with a net profit attributable to shareholders of around HK$630 million. The performance growth is mainly due to the company's rapid growth in drug revenue and BD revenue. In 2025, the company will continue to advance its globalization process and complete two BD transactions for the year. Ping An Securities stated that the company's core product, Albutinib, is steadily increasing in sales volume, with a comprehensive layout around hematologic malignancies, autoimmunity, and solid tumors, while steadily advancing its R&D pipeline. In addition, the company is actively engaged in external cooperation, achieving two external licensing and cooperation transactions in 2025, with corresponding upfront payments and future milestone revenue recognition, leading to upward adjustments in revenue forecasts for 2025-2027 to HK$2.371 billion, HK$2.575 billion, and HK$2.732 billion respectively, with revenue growth rates of 134.9%, 8.6%, and 6.1% for the years 2025-2027. The "recommended" rating is maintained.